{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:57:16Z","timestamp":1793051836173,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmcl.2026.130665","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:34:36Z","timestamp":1776494076000},"page":"130665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pyridine-2,6-dicarboxylic acid derivatives of potential antileishmanial activity: synthesis, biological evaluation, and in-silico studies"],"prefix":"10.1016","volume":"137","author":[{"given":"Husain","family":"Saqer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abd","family":"El-Fattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan A.","family":"Bekhit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130665_bb0005","first-page":"25","article-title":"Ongoing presence of Leishmania major cutaneous leishmaniasis in Mauritania, 2016\u20132024","author":"El Moctar","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bmcl.2026.130665_bb0010","first-page":"18","article-title":"Global, regional, and national burden of Visceral leishmaniasis, 1990\u20132021: findings from the global burden of disease study 2021","author":"Zhang","year":"2025","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.bmcl.2026.130665_bb0015","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.4103\/amsr.amsr_57_24","article-title":"Visceral leishmaniasis: recent updates","volume":"4","author":"Chakravarty","year":"2025","journal-title":"Ann Med Sci Res"},{"key":"10.1016\/j.bmcl.2026.130665_bb0020","first-page":"763","article-title":"Treatment of mucocutaneous leishmaniasis \u2013 A systematic review","volume":"22","author":"Fischer","year":"2024","journal-title":"JDDG - J German Soc Dermatol"},{"key":"10.1016\/j.bmcl.2026.130665_bb0025","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acsinfecdis.4c00231","article-title":"Innovating leishmaniasis treatment: A critical chemist\u2019s review of inorganic nanomaterials","volume":"10","author":"Bessa","year":"2024","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2026.130665_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0315710","article-title":"Safety profile of miltefosine in the treatment of cutaneous leishmaniasis","volume":"19","author":"Ribeiro","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.bmcl.2026.130665_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117392","article-title":"Synthesis and mechanistic insights of Coumarinyl-Indolinone hybrids as potent inhibitors of Leishmania major","volume":"288","author":"Batran","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130665_bb0040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1021\/acs.biomac.4c01273","article-title":"Degradable theranostic polyurethane for macrophage-targeted antileishmanial drug delivery","volume":"26","author":"Bag","year":"2025","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.bmcl.2026.130665_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13100835","article-title":"Molecular mechanisms of drug resistance in Leishmania spp","volume":"13","author":"Moncada-Diaz","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.bmcl.2026.130665_bb0050","first-page":"12","article-title":"Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapies","author":"Bhusal","year":"2025","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.bmcl.2026.130665_bb0055","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1021\/acsomega.4c06146","article-title":"In silico structural insights and potential inhibitor identification based on the benzothiazole core for targeting Leishmania major pteridine reductase 1","volume":"10","author":"de O. Viana","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmcl.2026.130665_bb0060","article-title":"Natural product identification and molecular docking studies of Leishmania major pteridine reductase inhibitors","volume":"18","author":"Arthur","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmcl.2026.130665_bb0065","doi-asserted-by":"crossref","DOI":"10.1007\/s40203-024-00247-8","article-title":"Antileishmanial natural products as potential inhibitors of the Leishmania pteridine reductase: insights from molecular docking and molecular dynamics simulations","volume":"12","author":"Adomako","year":"2024","journal-title":"In Silico Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130665_bb0070","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5c01799","article-title":"Design of 2-aminobenzothiazole derivatives targeting trypanosomatid PTR1 by a multidisciplinary fragment hybridization approach","author":"Panecka-hofman","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130665_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph18081237","article-title":"Identification of potential pteridin reductase-1 inhibitors for the treatment of leishmaniasis: a bioinformatics approach","volume":"18","author":"J\u00fanior","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmcl.2026.130665_bb0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1039\/D4MD00632A","article-title":"A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis","volume":"16","author":"Dwivedi","year":"2024","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmcl.2026.130665_bb0085","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.2147\/DDDT.S513461","article-title":"Exploring the potential of pyridine carboxylic acid isomers to discover new enzyme inhibitors","volume":"19","author":"Yaqoob","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmcl.2026.130665_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.128962","article-title":"Novel 2,6-disubstituted pyridine hydrazones: synthesis, anticancer activity, docking studies and effects on caspase-3-mediated apoptosis","volume":"1223","author":"\u015eenkarde\u015f","year":"2021","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmcl.2026.130665_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s13065-023-01111-0","article-title":"Synthesis, antileishmanial, antimalarial evaluation and molecular docking study of some hydrazine-coupled pyrazole derivatives","volume":"18","author":"Berhe","year":"2024","journal-title":"BMC Chem"},{"key":"10.1016\/j.bmcl.2026.130665_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114959","article-title":"New antileishmanial quinoline linked isatin derivatives targeting DHFR-TS and PTR1: design, synthesis, and molecular modeling studies","volume":"246","author":"Sabt","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130665_bb0105","doi-asserted-by":"crossref","first-page":"37131","DOI":"10.1039\/D4RA04965A","article-title":"Antileishmanial potential of thiourea-based derivatives: design, synthesis and biological activity","volume":"14","author":"Hadi","year":"2024","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmcl.2026.130665_bb0110","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1107\/S2053230X22002795","article-title":"Crystal structure of the ternary complex of Leishmania major pteridine reductase 1 with the cofactor NADP+\/NADPH and the substrate folic acid","volume":"78","author":"Dello","year":"2022","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"10.1016\/j.bmcl.2026.130665_bb0115","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/ci100436p","article-title":"FRED pose prediction and virtual screening accuracy","volume":"51","author":"McGann","year":"2011","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmcl.2026.130665_bb0120","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s10822-012-9584-8","article-title":"FRED and HYBRID docking performance on standardized datasets","volume":"26","author":"McGann","year":"2012","journal-title":"J Comput Aided Mol Des"},{"key":"10.1016\/j.bmcl.2026.130665_bb0125","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1021\/ci100031x","article-title":"Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and Cambridge Structural Database","volume":"50","author":"Hawkins","year":"2010","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmcl.2026.130665_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2026.130665_bb0135","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: a webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmcl.2026.130665_bb0140","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/14756366.2022.2150763","article-title":"Spiro heterocycles bearing piperidine moiety as potential scaffold for antileishmanial activity: synthesis, biological evaluation, and in silico studies","volume":"38","author":"Mohamed","year":"2023","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmcl.2026.130665_bb0145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jmb.2005.06.076","article-title":"Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design","volume":"352","author":"Sch\u00fcttelkopf","year":"2005","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2026.130665_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejmech.2019.06.051","article-title":"Synthesis, in vitro biological evaluation and in silico studies of certain arylnicotinic acids conjugated with aryl (thio)semicarbazides as a novel class of anti-leishmanial agents","volume":"179","author":"Eldehna","year":"2019","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:24:29Z","timestamp":1777613069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26001320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"alternative-id":["S0960894X26001320"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130665","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyridine-2,6-dicarboxylic acid derivatives of potential antileishmanial activity: synthesis, biological evaluation, and in-silico studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130665"}}